What the New Research Reveals
A recent large-scale observational study has provided a stark warning for users of GLP-1 medications. Published in The Lancet Regional Health Europe, the Italian study analysed data from over 80,000 people with type 2 diabetes. It found that those who
stopped their GLP-1 treatment had approximately double the combined risk of a non-fatal heart attack, non-fatal stroke, or death from any cause compared to those who continued the therapy. This translates to about four major events per 100 people each year among those who stopped, versus two per 100 for those who remained on the medication. While the study is observational and cannot prove direct causation, its findings strongly suggest that the protective benefits of these drugs are lost upon cessation.
Understanding the Increased Risks
The primary risk highlighted by the new study is cardiovascular. However, this is part of a broader pattern seen across multiple studies: when GLP-1 treatment ends, its benefits tend to reverse. This includes the return of weight that was lost and the reversal of improvements in cardiometabolic factors like blood pressure, cholesterol, and blood sugar levels. Studies like the STEP 1 trial extension showed that one year after stopping semaglutide, participants had regained, on average, two-thirds of the weight they had lost. This weight regain is not just a cosmetic issue; it brings back the health risks associated with obesity and poor metabolic health. The body’s hunger signals and cravings, which were suppressed by the medication, return, making it difficult to maintain the lower weight.
The Discontinuation Dilemma
Given these risks, why do so many people—up to two-thirds in some cases—stop taking GLP-1s within a year? The reasons are complex. A national survey identified the leading causes as high cost and lack of insurance coverage (affecting over a third of users), followed closely by side effects like nausea, vomiting, and other gastrointestinal issues. Other factors include medication shortages, reaching a weight loss goal and believing the treatment is no longer needed, or simply a preference to not be on a long-term injectable medication. For many, the decision is a difficult trade-off between the drug's benefits and its financial or physical costs.
A Lifelong Management Tool?
The latest research reinforces what many doctors have been saying: GLP-1s should be viewed as treatments for chronic diseases, not as short-term fixes. Obesity and type 2 diabetes are long-term conditions that require continuous management, much like high blood pressure or high cholesterol. The medications work by managing the underlying biology of these diseases; when the drug is withdrawn, the biological drivers of appetite and metabolism return to their previous state. The findings from discontinuation studies strongly suggest that to maintain the weight loss and cardiovascular benefits, ongoing treatment is required. This shifts the perspective from 'taking a course of medication' to 'managing a chronic condition' for the long haul.
What This Means For You
If you are currently taking a GLP-1 medication, or considering it, this research is crucial for setting realistic expectations. These are not 'cure-all' drugs but rather powerful management tools that require long-term commitment. It is vital to never stop the medication without first consulting your doctor. They can help you weigh the risks and benefits and potentially explore strategies to mitigate side effects or manage costs. If stopping is necessary, a plan should be in place to monitor for weight regain and the return of other health risks, focusing heavily on sustained lifestyle changes in diet and exercise. The key takeaway is that discontinuation is a significant medical decision with potentially serious health consequences.
















